The DOI matches its Crossref record; 212 of the 213 references it cites were found in a registry or an index.
Targeting IL-6 trans-signalling: past, present and future prospects
Open accessAbstract
Interleukin-6 (IL-6) is a key immunomodulatory cytokine that affects the pathogenesis of diverse diseases, including autoimmune diseases, chronic inflammatory conditions and cancer. Classical IL-6 signalling involves the binding of IL-6 to the membrane-bound IL-6 receptor α-subunit (hereafter termed ‘mIL-6R’) and glycoprotein 130 (gp130) signal-transducing subunit. By contrast, in IL-6 trans-signalling, complexes of IL-6 and the soluble form of IL-6 receptor (sIL-6R) signal via membrane-bound gp130. A third mode of IL-6 signalling — known as cluster signalling — involves preformed complexes of membrane-bound IL-6–mIL-6R on one cell activating gp130 subunits on target cells. Antibodies and small molecules have been developed that block all three forms of IL-6 signalling, but in the past decade, IL-6 trans-signalling has emerged as the predominant pathway by which IL-6 promotes disease pathogenesis. The first selective inhibitor of IL-6 trans-signalling, sgp130, has shown therapeutic potential in various preclinical models of disease and olamkicept, a sgp130Fc variant, had promising results in phase II clinical studies for inflammatory bowel disease. Technological developments have already led to next-generation sgp130 variants with increased affinity and selectivity towards IL-6 trans-signalling, along with indirect strategies to block IL-6 trans-signalling. Here, we summarize our current understanding of the biological outcomes of IL-6-mediated signalling and the potential for targeting this pathway in the clinic. This Review details the discovery of the interleukin-6 (IL-6) trans-signalling pathway and the subsequent development of biologics that specifically inhibit this pathway. Emerging evidence suggests that specifically targeting IL-6 trans-signalling can reduce pathological disease-promoting activities of IL-6 without blocking the protective actions of IL-6 in infection and tissue repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In MM cells, the JAK/STAT3 pathway is triggered by cytokines from the gp130 receptor family, such as IL-6, leukemia inhibitory factor (LIF), and oncostatin-M (OSM).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the binding of IL-6 to its receptor (IL-6R) leads to the activation of JAK1, which phosphorylates STAT3, thereby activating the JAK/STAT pathway [108].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Soluble gp130Fc, named olamkicept or TJ301, is consists of two soluble human gp130 proteins fused with the Fc of human IgG, and selectively targets the IL-6-sIL-6R complex [79].”
From The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As IL-6 classic signaling plays crucial roles in the initiation of inflammation and the host defense against pathogen infection, global blockade of IL-6 signaling may reduce the induction of hepatic acute-phase proteins upon infection, such as Listeria monocytogenes [79].”
From The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases (2024) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Self-citationHirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045 · cited 1×
“Dysregulated IL-6 signalling is a hallmark of infections, including SARS-CoV-2, that are characterized by hyperinflammation 137–145 , with high IL-6 levels in patients with COVID-19 being implicated in the depletion of CD4 + T cells, CD8 + T cells and natural killer cells 146 .”
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 2×
“Studies in IL-6-deficient mice showed that IL-6 contributes to the pathogenesis of many inflammatory diseases, including bacterial and viral infections 66 , arthritis 67,68 , experimental colitis 69 and multiple sclerosis 70 .”
Gauldie, J., Richards, C. D., Harnish, D. C., Lansdorp, P. M., & Baumann, H. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7251 · Cited by 1,635
Research works printed but not linked: 1
- Kang, S., Narazaki, M., Metwally, H. & Kishimoto, T. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 2020, 5 (2020).
Cited by
Sorted by citations
Items 401–500 of 555
The role of interleukin 6 in the development of cardiovascular pathology
Nasonov, E. L., Fomicheva, O. A., Baranov, A. A., Попкова, Т. В., & MIu, S. (2026) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2026-335-357 · Cited by 1
Refining therapeutic targeting of interleukin-6 by signalling mode selectivity
Rose‐John, S., Waetzig, G. H., & Schreiber, S. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01536-x · Cited by 1
Self-citationUeda, Y., Kawaguchi, N., Inomata, Y., Arima, J., Ishida, M., Ito, Y., Lee, S., & Taniguchi, K. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70782 · Cited by 1
Identification of Prognostic Factors and Regulatory Pathways in Porto‐Sinusoidal Vascular Disorder
Heo, S., Yoon, D. K., Shin, S., Youn, D., Yoo, Y., Song, I. H., Kang, H. J., Yoon, Y., Kim, K., Lee, S. S., et al. (2026) · Liver International · doi:10.1111/liv.70898 · Cited by 1
Therapeutic Potentials and Candidates for COVID-19
Rami, M. R., Meskini, M., Khozani, N. R., Forouzandehdel, S., Momtaz, S., Ghosh, S. B., Rezaei, N., & Abdolghaffari, A. H. (2023) · Iranian Journal of Science · doi:10.1007/s40995-023-01488-6 · Cited by 1
Zhang, X. M., Ma, Z., Mao, C., Zhang, J., & Ma, Z. (2023) · Pharmacognosy Magazine · doi:10.1177/09731296231197077 · Cited by 1
Zhang, S., Zhang, W., Sun, H., Xue, R., & Lv, Q. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20474 · Cited by 1
Li, J., Zheng, X., Yu, C., Li, P., & Xiao, G. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104194 · Cited by 1
Sharma, L., Singh, R., Ngeow, C., van der Geest, R., Duray, A. M., Tolman, N. J., McVerry, B. J., Cruz, C. S. D., Alcorn, J. F., Bain, W., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70232 · Cited by 1
Olaniyan, M. F., Odegbemi, O. B., Tijani, A. W., Ojediran, T. B., Adeniran, M. T., Oniye, A. H., Adesina, O. O., Adejumo, B. I. G., Ajiboye, K. F., Mohammed, A. S., et al. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00696-6 · Cited by 1
Lu, C.-T., Ma, X., Liu, B., Wang, J., Luo, S., & Luo, Q. (2025) · Journal of International Medical Research · doi:10.1177/03000605251381574 · Cited by 1
Blocking interleukin-6 trans-signaling in AF: Promises and challenges
Martinez, E., & Li, N. (2023) · Heart Rhythm · doi:10.1016/j.hrthm.2023.09.005 · Cited by 1
FGF21 Counteracts Adipose Tissue Wasting in Cancer-Associated CachexiaPreprint
Österreicher, T., Kührer, K., Höbler, A.-L., Berghoff, A. S., Gottmann, L., Udonta, F., Körbelin, J., Pollak, D. D., Hengstschläger, M., Loges, S., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4896832 · Cited by 1
Papetti, A. V., Ma, Z., Ng, M., Jin, M., Levison, S. W., & Jiang, P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.26.728058 · Cited by 1
Başarıya Giden Yol: Spor, Beden Eğitimi ve Psikolojik Yetenek
Özcan, V., & Günay, M. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub246.c1066
Evaluation of the Relationship between Exercise, Osteocalcin, Insulin, and Interleukin-6
Beyazçiçek, Ö., & Beyazçiçek, E. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub246.c1062
Erken Çocukluk Eğitiminde Motor Gelişim İçin Oyunun Önemi
Ünver, D. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub246.c1061
Protective effects of ginsenosides on macrophages subjected to simulated weightlessness
Li, B., Chen, T., Ji, E., Chen, Y., Hu, Q., & Li, Q. (2023) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2023.10.004
李, 雨. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441031
(2024) · Microbiology Australia · doi:10.1071/mav45n1
ADAM17 regulates hepatic DNA damage repair and tumour formationPreprint
Reichert, M., Halwachs, B., Bolik, J., Senftleben, A., Krause, F., Conrady, L., Bauer, R., Rachmilewitz, J., Horejs‐Hoeck, J., Rose‐John, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.30.605791
Self-citationThe Biology of Interleukin-6: A Major Target in Anti-Inflammatory Therapies
Rose‐John, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00103-4
Self-citationDugage, M. R., Lambotte, O., Mariette, X., & Marabelle, A. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.007
The Role of IL-6 Trans-Signaling in the Pathogenesis of Perioperative Neurocognitive Disorders
Chang, O. L. B., Kim, H. S., & Maze, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_170-1
Gu, Z., Gao, A., Ma, X., Wang, X., & Qiu, C. (2025) · Research Square · doi:10.21203/rs.3.rs-5966082/v1
Liu, Y., Kong, X., Sun, Q., Cui, T., Xu, S., & Ding, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317369
Shunkina, D. A., Dakhnevich, A. Y., Shupletsova, V. V., Хазиахматова, О. Г., Shunkin, E. O., Vulf, M. A., Bograya, M., Тодосенко, Н. М., Георгиевна, Ч. Е., & Litvinova, L. S. (2025) · Cell and Tissue Biology · doi:10.1134/s1990519x24600790
Interleukin-6 signalling: what rheumatologists should know and expect
Rodolfi, S., Maślińska, M., & Selmi, C. F. (2025) · Reumatologia/Rheumatology · doi:10.5114/reum/204012
Deng, H., Ke, Y., Weng, S., Hu, L., Zhang, W., Sun, Y., Yang, L., Wang, X., Feng, M., Guo, W., et al. (2025) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2025.110402
Trunfio, M., Iudicello, J. E., Riggs, P. K., Kallianpur, A. R., Hulgan, T., Ellis, R. J., & Letendre, S. L. (2025) · Viruses · doi:10.3390/v17060749
Роль интерлейкина-6 и растворимого гликопротеида 130 в развитии атеросклероза коронарных артерий
Каминный, А. И., Shuvalova, Y. A., Москаленко, С. А., Каминная, В. А., Пиксина, Г. Ф., & Палеев, Ф. Н. (2025) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2025.02.0004
Miao, J., Wang, L., & Min, F. (2025) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/200267
Couch, A. C. M., Perry, B. I., Rosoff, D. B., Palmer, E. R., Rogers, J. C., Ray, D. W., & Upthegrove, R. (2025) · Research Square · doi:10.1101/2025.07.23.666268
Kouzu, K., Mochizuki, S., Tsujimoto, H., Ishibashi, Y., Nearchou, I. P., Ohara, K., Fujishima, S., Kishi, Y., Matsukuma, S., Okada, Y., et al. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104222
Lilan, W., Ru, Z., Shengnan, G., Lv, N., Kerou, L., & Qiao, H. (2025) · Research Square · doi:10.21203/rs.3.rs-7260308/v1
The Role of IL-6 Trans-Signaling in the Pathogenesis of Perioperative Neurocognitive Disorders
Chang, O. L. B., Kim, H. S., & Maze, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_170
Soluble Glycoprotein 130Fc Reduces Controlled Cortical Impact-Induced Cognitive Deficits in Rats
Russell, A. L., Dimeo, E. G., Mandava, A., Nasser, L., Convertino, N., Padamati, S., Gober, I. G., Scott, J. A., Patel, V., Carlson, J. C., et al. (2025) · Neurotrauma Reports · doi:10.1177/2689288x251377032
Liu, Y., Song, N., Wang, Q., Cui, P., & Min, D. (2025) · Brain and Behavior · doi:10.1002/brb3.70772
He, C., Tan, L., Liang, C., Luo, J., Ke, X., Wu, S., & He, J. (2025) · Immunobiology · doi:10.1016/j.imbio.2025.153122
Altê, G. A., & Rodrigues, A. L. S. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_9
Bergo, I., SLEVIN, M. A., Pastorello, Y., Höhne, A., & Tero-Vescan, A. (2025) · Life · doi:10.3390/life15101593
The burden of osteoarthritis: Lifespan matters
Rocha, F. A. C. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.10.017
Comparison of surgical trauma between three endoscopic thyroidectomy approaches and open surgery
Qin, J., Ren, H. Y., Li, L., Wu, Y., Xia, T.-M., Wang, X., & He, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1677239
Liu, T., Zhao, Y., Zhuang, H., Zhang, L., Liu, Z., & Lei, B. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149444
Lanton, T., Eidelshtein, D., Rachmilewitz, J., Abramovitch, R., Pappo, O., Udi, S., Baraghithy, S., Tam, J., Perles, S., Williams, E. G., et al. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100819
Self-citationPhysiological roles and therapeutic potential of the purinergic P2X7 receptor
Dunker, C., Gross, S., Vinnenberg, L., Prinz, A., Koch, O., & Junker, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00063-7
Gober, I. G., Russell, A. L., Shick, T. J., Vagni, V., Carlson, J. C., Kochanek, P. M., & Wagner, A. K. (2024) · Figshare · doi:10.6084/m9.figshare.26730082
Gober, I. G., Russell, A. L., Shick, T. J., Vagni, V., Carlson, J. C., Kochanek, P. M., & Wagner, A. K. (2024) · Figshare · doi:10.6084/m9.figshare.26730079
Gober, I. G., Russell, A. L., Shick, T. J., Vagni, V., Carlson, J. C., Kochanek, P. M., & Wagner, A. K. (2024) · Figshare · doi:10.6084/m9.figshare.26730073
Gober, I. G., Russell, A. L., Shick, T. J., Vagni, V., Carlson, J. C., Kochanek, P. M., & Wagner, A. K. (2024) · Figshare · doi:10.6084/m9.figshare.26730076
Targeting pro-inflammatory signaling in atherosclerotic stroke
Živković, L. (2025) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.35958
Transcriptional Analysis of CCR5 upon Cytokine Stimulation of Prostate Cancer Cells
Amran, A. S. (2024) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Assessment of local humoral immunity status in oral fluid of smokers: a cross-sectional study
Krasilnikov, I. R., & Lazarenko, L. L. (2025) · Cytokines and inflammation · doi:10.17816/ci689570
Zhou, B., Peng, W., & Tong, D. (2025) · Open Medicine · doi:10.1515/med-2025-1269
Kulyova, A. A., Kulyova, S. A., Хабарова, Р. И., Senchurov, E. M., Михайлова, Е. А., Borokshinova, K. M., Ignatova, V. S., Prosekina, E. A., & Вершинина, Т. Л. (2025) · Podderživaûŝaâ terapiâ v onkologii. · doi:10.17650/3034-2473-2025-2-3-76-84
Каминный, А. И., Shuvalova, Y. A., Kaminnaya, V. I., & Палеев, Ф. Н. (2025) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin2025200415
Wen, L., Lou, S., Zhang, L., Zhou, H., Tan, Y., Ai, K., Liu, X., Zhang, L., Ding, W., & Huang, Y. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121172
Cytokine Alterations and Targeting in Neurodegeneration: Role of Nanomaterials
Naeem, A., & Raza, S. S. (2026) · Springer eBooks · doi:10.1007/978-981-95-5088-3_5
Geng, D., Xu, H., Gou, J., Wang, Y., Chen, Y., Hong, S. L., & Kuang, L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1691782
Warum das C-reaktive Protein beim SLE (meist) nicht hoch ist
Klapproth, E., Hempel, M., Leuchten, N., Rose‐John, S., Korb‐Pap, A., & Aringer, M. (2026) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-026-01779-4
Self-citationXie, Y., Tian, Y., Liu, L., Zhou, J., Cui, J., Yang, L., Ge, T., He, G., Li, W., & Yu, J. (2026) · Research Square · doi:10.21203/rs.3.rs-8632354/v1
Therapeutic targets for fibro-inflammation in Graves’ orbitopathy
Kang, Y. J., & Yoon, J. S. (2025) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo-d-25-00057
Feng, Z., Gu, Z., Gao, A., Ma, X., Wang, X., Qiu, C., & Liu, S. (2026) · Research Square · doi:10.21203/rs.3.rs-5966082/v2
Nghiên cứu tạo mô hình chuột mang khối u ghép bằng tế bào HT29 Hyper-IL-6
Ngọc, N. N., Ly, N. T. M., Toàn, N. T., Toàn, N. L., & Cường, B. K. (2026) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v199i2.4585
Li, B., Ji, X., Xiang, Z., Zhao, F., Zhi, H., Sun, Z., Liu, T., Luo, Y., Chen, X., Feng, R., et al. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.03.001
Interferon–JAK–STAT Axis in Bone Metabolism
Yokota, S., Mizuno, M., Umemoto, A., Morita, W., & Park‐Min, K. (2026) · Current Osteoporosis Reports · doi:10.1007/s11914-026-00960-7
Županič, A., Edalat, S. G., Burja, B., Busch, M. P., Kuret, T., Ižanc, N., Zingg, R. S., Pich, L. M. M., Sodin‐Šemrl, S., Distler, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.23.713616
Sgp130Fc regulates IL-6/JAK2/STAT3 trans-signaling pathway in rat vocal fold fibroblast activation
Gao, M., Li, X., Wang, H., Lin, Y., Hu, R., & Xu, W. (2026) · Experimental Cell Research · doi:10.1016/j.yexcr.2026.115019
Tarrass, M. A. (2023) · theses.fr (ABES) · doi:10.70675/aea61e27z0cadz4558za7acz92d960d99b81
wang, L., xing, P., Zhao, X.-K., Song, X., Wei, M.-X., You, D., Lei, L.-L., Xu, R., Wang, R., Ma, L., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10792-x
IL-6-JAK2-STAT3 Signaling Pathway and the Pathogenesis of Chronic Tonsillitis
Li, S. X., Li, X., Lu, J., Yang, H., Yang, H., & Zhang, H. (2026) · Journal of Interferon & Cytokine Research · doi:10.1177/10799907261442845
Zhang, X. F., Jiang, H., Chen, C., & Ma, J. (2026) · Research Square · doi:10.21203/rs.3.rs-9242248/v1
Construction and evaluation of a graded rat model for smoke inhalation lung injury
Zhou, Y. Z., Shi, F., Zhang, Y., Xu, Y., Du, Y., Zhang, J., Gao, Y., & Zhou, Y. (2026) · Journal of Acute Disease · doi:10.4103/jad.jad_29_26
Yang, J., Wang, Y., Huang, J., Zhang, J., & Xie, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1794095
Hibić, H., Dervišević, E., Fajkić, A., Hodžić, A., Chupin, A., & Sher, E. K. (2026) · Life · doi:10.3390/life16050736
Zhao, L., Tang, Z., & Zhu, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1825206
Wang, J.-W., Xun, J.-J., & Jian, L.-N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1846052
Tjiptaningrum, A., Yusra, Y., Kusmardi, K., Arsianti, A., Mustokoweni, S., & Fadilah, F. (2026) · Applied Biosciences · doi:10.3390/applbiosci5020041
Molecular and functional consequences of the Cdc42 C81Y mutation in immune-associated malignancy
Chong, C. F., Nordin, S. A., Syafruddin, S. E., Ismail, N. I., & Mokhtar, A. M. A. (2026) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2026.110876
Liu, X., Bian, X., Han, S., Li, B., Song, J., Liang, C., Zhou, J., & Chen, X. (2026) · Mediators of Inflammation · doi:10.1155/mi/2600849
Sohail, Z., Hadi, N. B. A., Rehman, A., Asghar, M., & Zaman, F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1833900
Tanzi, R. E., Castro, R., Gavrilles, E. P., & Choi, S. H. (2026) · Research Square · doi:10.21203/rs.3.rs-9619714/v1
Zhao, G., Fu, H., Liu, F., Duan, M., & Wang, T. (2026) · BMC Surgery · doi:10.1186/s12893-026-03919-8
Aromolaran, K. A., & Aromolaran, A. S. (2026) · The Journal of Physiology · doi:10.1113/jp291366
Ahmad, A., & Saleem, A. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05514-3
Jeong, S., Lee, J. M., Koh, J., & Lee, D. (2026) · Journal of Orthopaedic Research® · doi:10.1002/jor.70235
Chen, L., Jin, S., Wang, Z., Subinu, A., Mo, F., Huang, J., & Wang, H. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02158-y
Trans-presentation of IL-6Rα by macrophages drives colorectal cancer development
Gong, F., Zhang, Q., Qian, J. P., He, Y., Du, K., Fang, H., Li, Q., Yang, Y., Wei, H.-X., Jin, T., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117549
Nan, Y.-L., Sun, T.-H., Kai-jie, R. E. N., Min, T., Ma, Y.-Y., Xie, X., Deng, X.-Y., Peng, Y.-C., Liu, Y.-Y., Tong, S.-Y., et al. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.120954
Ambríz-Zárate, J. S., Báez‐Ruíz, A., Saderi, N., & Salgado‐Delgado, R. (2026) · Journal of Biological Rhythms · doi:10.1177/07487304261459132
Zhou, D., Tang, K., Zhao, Y., Yue, H., Ma, J., & Zha, H. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13819-0
Interleukin-6: A potential link in the pathophysiology of restless legs syndrome
Kalkman, H. O., & Smigielski, L. (2026) · Immunology Letters · doi:10.1016/j.imlet.2026.107208
Interleukin-6 is critical in the development of pulmonary vascular disease in Gcn2- deficient mice
Schwiening, M., Gao, Q., Southwood, M. R., Crosby, A., Moore, S., Valer, J. A., Veale, N., Dunmore, B. J., Upton, P. D., Thompson, A. A. R., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2531623123
Kong, D., Wang, Y., Chen, X., Hu, C., Zhang, B., & Chen, X. P. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71006
Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies
Nishimura, Y., Habermann, T. M., Dispenzieri, A. A., & van Rhee, F. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2702010
Zhang, L., Qiu, X., Zhou, Y., Ming-li, L., Guo, L., Qi, F., Wu, Y., Meng, C., & Liu, G. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153509
Ryguła, I., Rosiek, V., & Kos‐Kudła, B. (2026) · Cancers · doi:10.3390/cancers18142257
Huang, X., Yan, H., Bai, J., Bao, S., Wang, Y., & Gao, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1882156
Serum meprin α levels for the detection of systemic inflammatory response syndrome
Beckinger, S., Mengel, M., Lindner, M., Köhling, V., Peters, F., Götting, I., Stoske, J., Rusch, J., Radke, D. I., Schädler, D., et al. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01570-w
Elkoshi, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1864104
Metadata
- Authors
- Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J.
- Affiliations
- Hudson Institute of Medical Research (AU)
- Otto-von-Guericke-Universität Magdeburg (DE)
- Heinrich Heine University Düsseldorf (DE)
- Corresponding author
- Scheller, Jürgen
- Venue
- Nature Reviews Immunology
- Published
- 2023-04-17
- Volume
- 23
- Issue
- 10
- Pages
- 666-681
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC10108826
- OpenAlex
- W4366085911
- Semantic Scholar
- 5ffbde604bb1ef36987e5c29a105b9a8541a3137
- Cited by
- 524
- References
- 213
- Citations by year
- 2026: 146 · 2025: 184 · 2024: 151 · 2023: 43
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (LC170062)
- Deutsche Forschungsgemeinschaft (CRC877, SFB 877, CRC 841, 125440785)
- Deutsche Krebshilfe
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- interleukin-6, IL-6 trans-signalling, soluble IL-6 receptor, gp130, sgp130, IL-6 receptor alpha, inflammatory bowel disease, autoimmune disease, chronic inflammation, cancer, cytokine therapy
- MeSH terms
- Humans, Neoplasms, Interleukin-6, Cytokines, Receptors, Interleukin-6, Cytokine Receptor gp130
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
